On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA’s Category 2 “do not compound” list would be moved back to Category 1 status.
This anticipated regulatory change means that compounding pharmacies could start making these peptides, such as BPC-157, CJC-1295, and many more, as soon as next month.
If you would like to be kept up-to-date on the FDA changes and notified when Mix Pharmacy begins offering these products, please fill out the form below to join our peptides email list.